Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia

Cancer Cell

Volumn 27, Issue 3, 2015, Pages 409-425

  Geng, Huimin ^a   Hurtz, Christian ^a   Lenz, Kyle B ^b,c   Chen, Zhengshan ^a   Baumjohann, Dirk ^d,o   Thompson, Sarah ^b,c   Goloviznina, Natalya A ^b,c   Chen, Wei Yi ^e,f   Huan, Jianya ^b,c   LaTocha, Dorian ^c   Ballabio, Erica ^g   Xiao, Gang ^a   Lee, Jae Woong ^a   Deucher, Anne ^a   Qi, Zhongxia ^a   Park, Eugene ^a   Huang, Chuanxin ^h   Nahar, Rahul ^a   Kweon, Soo Mi ^a   Shojaee, Seyedmehdi ^a   Chan, Lai N ^a   Yu, Jingwei ^a   Kornblau, Steven M ⁱ   Bijl, Janetta J ^j   Ye, B Hilda ^k   Mark Ansel, K ^d   Paietta, Elisabeth ^k   Melnick, Ari ^h   Hunger, Stephen P ^l   Kurre, Peter ^b,c   Tyner, Jeffrey W ^c,m   Loh, Mignon L ^a   Roeder, Robert G ^e   Druker, Brian J ^c,n   Burger, Jan A ⁱ   Milne, Thomas A ^g   Chang, Bill H ^b,c   Müschen, Markus ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e ROCKEFELLER UNIVERSITY   (United States)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^k ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^l CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^m OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁿ HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^o UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PRE B CELL RECEPTOR; PROTEIN BCL 6; PROTEIN KINASE SYK INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; STAT5 PROTEIN; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; ONCOPROTEIN; PBX1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE; SYK PROTEIN, HUMAN; TCF3 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; FEEDBACK SYSTEM; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CLINICAL TRIAL (TOPIC); GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; PRE B LYMPHOCYTE; UPREGULATION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CLINICAL TRIALS AS TOPIC; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; PHOSPHATIDYLINOSITOL 3-KINASE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRECURSOR CELLS, B-LYMPHOID; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; SYK KINASE; UP-REGULATION;

EID: 84924266365     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.02.003     Document Type: Article

References (45)

1. Bayly R., Chuen L., Currie R.A., Hyndman B.D., Casselman R., Blobel G.A., LeBrun D.P. E2A-PBX1 interacts directly with the KIX domain of CBP/p300 in the induction of proliferation in primary hematopoietic cells. J.Biol. Chem. 2004, 279:55362-55371.
2. Bicocca V.T., Chang B.H., Masouleh B.K., Muschen M., Loriaux M.M., Druker B.J., Tyner J.W. Crosstalk between ROR1 and the pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012, 22:656-667.
3. Burger J.A., Okkenhaug K. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies. Nat. Rev. Clin. Oncol. 2014, 11:184-186.
4. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., Grant B., Sharman J.P., Coleman M., Wierda W.G., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N.Engl. J. Med. 2013, 369:32-42.
5. Byrd J.C., O'Brien S., James D.F. Ibrutinib in relapsed chronic lymphocytic leukemia. N.Engl. J. Med. 2013, 369:1278-1279.
6. Cerchietti L.C., Yang S.N., Shaknovich R., Hatzi K., Polo J.M., Chadburn A., Dowdy S.F., Melnick A. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects invitro and invivo. Blood 2009, 113:3397-3405.
7. Chen L., Juszczynski P., Takeyama K., Aguiar R.C., Shipp M.A. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood 2006, 108:3428-3433.
8. Chen L., Monti S., Juszczynski P., Ouyang J., Chapuy B., Neuberg D., Doench J.G., Bogusz A.M., Habermann T.M., Dogan A., et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013, 23:826-838.
9. Cheng S., Coffey G., Zhang X.H., Shaknovich R., Song Z., Lu P., Pandey A., Melnick A.M., Sinha U., Wang Y.L. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011, 118:6342-6352.
10. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., Kohlhammer H., Lamy L., Zhao H., Yang Y., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
11. Duy C., Yu J.J., Nahar R., Swaminathan S., Kweon S.M., Polo J.M., Valls E., Klemm L., Shojaee S., Cerchietti L., et al. BCL6 is critical for the development of a diverse primary B cell repertoire. J.Exp. Med. 2010, 207:1209-1221.
12. Duy C., Hurtz C., Shojaee S., Cerchietti L., Geng H., Swaminathan S., Klemm L., Kweon S.M., Nahar R., Braig M., et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 2011, 473:384-388.
13. Geng H., Brennan S., Milne T.A., Chen W.Y., Li Y., Hurtz C., Kweon S.M., Zickl L., Shojaee S., Neuberg D., et al. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer Discov. 2012, 2:1004-1023.
14. Gopal A.K., Kahl B.S., de Vos S., Wagner-Johnston N.D., Schuster S.J., Jurczak W.J., Flinn I.W., Flowers C.R., Martin P., Viardot A., et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N.Engl. J. Med. 2014, 370:1008-1018.
15. Guo B., Kato R.M., Garcia-Lloret M., Wahl M.I., Rawlings D.J. Engagement of the human pre-B cell receptor generates a lipid raft-dependent calcium signaling complex. Immunity 2000, 13:243-253.
16. Harvey R.C., Mullighan C.G., Wang X., Dobbin K.K., Davidson G.S., Bedrick E.J., Chen I.M., Atlas S.R., Kang H., Ar K., et al. Identification of novel cluster groups in pediatric high-risk B-precursor acutelymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010, 116:4874-4884.
17. Juszczynski P., Chen L., O'Donnell E., Polo J.M., Ranuncolo S.M., Dalla-Favera R., Melnick A., Shipp M.A. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood 2009, 114:5315-5321.
18. Kanzler H., Küppers R., Hansmann M.L., Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth ofadominant tumor clone derived from (crippled) germinal center B cells. J.Exp. Med. 1996, 184:1495-1505.
19. Ke J., Chelvarajan R.L., Sindhava V., Robertson D.A., Lekakis L., Jennings C.D., Bondada S. Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth. Mol. Cancer 2009, 8:132.
20. Kraus M., Alimzhanov M.B., Rajewsky N., Rajewsky K. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004, 117:787-800.
21. Leithäuser F., Bäuerle M., Huynh M.Q., Möller P. Isotype-switched immunoglobulin genes with a high load of somatic hypermutation and lack of ongoing mutational activity are prevalent in mediastinal B-cell lymphoma. Blood 2001, 98:2762-2770.
22. Nourse J., Mellentin J.D., Galili N., Wilkinson J., Stanbridge E., Smith S.D., Cleary M.L. Chromosomal translocation t(1;19) results in synthesis of a homeobox fusion mRNA that codes for a potential chimeric transcription factor. Cell 1990, 60:535-545.
23. Ochiai K., Maienschein-Cline M., Mandal M., Triggs J.R., Bertolino E., Sciammas R., Dinner A.R., Clark M.R., Singh H. A self-reinforcing regulatory network triggered by limiting IL-7 activates pre-BCR signaling and differentiation. Nat. Immunol. 2012, 13:300-307.
24. Okada T., Maeda A., Iwamatsu A., Gotoh K., Kurosaki T. BCAP: the tyrosine kinase substrate that connects B cell receptor to phosphoinositide 3-kinase activation. Immunity 2000, 13:817-827.
25. Osmond D.G. Proliferation kinetics and the lifespan of B cells in central and peripheral lymphoid organs. Curr. Opin. Immunol. 1991, 3:179-185.
26. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996, 381:751-758.
27. Ramadani F., Bolland D.J., Garcon F., Emery J.L., Vanhaesebroeck B., Corcoran A.E., Okkenhaug K. The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development. Sci. Signal. 2010, 3:ra60.
28. Rickert R.C. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat. Rev. Immunol. 2013, 13:578-591.
29. Ross M.E., Zhou X., Song G., Shurtleff S.A., Girtman K., Williams W.K., Liu H.C., Mahfouz R., Raimondi S.C., Lenny N., et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102:2951-2959.
30. Saijo K., Schmedt C., Su I.H., Karasuyama H., Lowell C.A., Reth M., Adachi T., Patke A., Santana A., Tarakhovsky A. Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat. Immunol. 2003, 4:274-279.
31. Sakaguchi N., Melchers F. Lambda 5, a new light-chain-related locus selectively expressed in pre-B lymphocytes. Nature 1986, 324:579-582.
32. Sanyal M., Tung J.W., Karsunky H., Zeng H., Selleri L., Weissman I.L., Herzenberg L.A., Cleary M.L. B-cell development fails in the absence of the Pbx1 proto-oncogene. Blood 2007, 109:4191-4199.
33. Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., Wright G., Shaffer A.L., Hodson D.J., Buras E., et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116-120.
34. Schweighoffer E., Vanes L., Mathiot A., Nakamura T., Tybulewicz V.L. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003, 18:523-533.
35. Shaffer A.L., Yu X., He Y., Boldrick J., Chan E.P., Staudt L.M. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000, 13:199-212.
36. Srinivasan L., Sasaki Y., Calado D.P., Zhang B., Paik J.H., DePinho R.A., Kutok J.L., Kearney J.F., Otipoby K.L., Rajewsky K. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139:573-586.
37. Swaminathan S., Huang C., Geng H., Chen Z., Harvey R., Kang H., Ng C., Titz B., Hurtz C., Sadiyah M.F., et al. BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nat. Med. 2013, 19:1014-1022.
38. Tibes R., Qiu Y., Lu Y., Hennessy B., Andreeff M., Mills G.B., Kornblau S.M. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol. Cancer Ther. 2006, 5:2512-2521.
39. Trageser D., Iacobucci I., Nahar R., Duy C., von Levetzow G., Klemm L., Park E., Schuh W., Gruber T., Herzog S., et al. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function. J.Exp. Med. 2009, 206:1739-1753.
40. Tyner J.W., Yang W.F., Bankhead A., Fan G., Fletcher L.B., Bryant J., Glover J.M., Chang B.H., Spurgeon S.E., Fleming W.H., et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2013, 73:285-296.
41. Wang L., Li L., Zhang H., Luo X., Dai J., Zhou S., Gu J., Zhu J., Atadja P., Lu C., et al. Structure of human SMYD2 protein reveals the basis of p53tumor suppressor methylation. J.Biol. Chem. 2011, 286:38725-38737.
42. Wang M.L., Rule S., Martin P., Goy A., Auer R., Kahl B.S., Jurczak W., Advani R.H., Romaguera J.E., Williams M.E., et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N.Engl. J. Med. 2013, 369:507-516.
43. Yang C., Lu P., Lee F.Y., Chadburn A., Barrientos J.C., Leonard J.P., Ye F., Zhang D., Knowles D.M., Wang Y.L. Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. Leukemia 2008, 22:1755-1766.
44. Ye B.H., Lista F., Lo Coco F., Knowles D.M., Offit K., Chaganti R.S., Dalla-Favera R. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993, 262:747-750.
45. Young R.M., Staudt L.M. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat. Rev. Drug Discov. 2013, 12:229-243.